Trial Profile
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial to Investigate the Safety and Efficacy of AV608 in Subjects With Idiopathic Detrusor Overactivity.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 02 Aug 2022
Price :
$35
*
At a glance
- Drugs AV 608 (Primary)
- Indications Overactive bladder
- Focus Therapeutic Use
- Sponsors Avera Pharmaceuticals
- 30 Jul 2022 This trial has been completed in Netherlands (Date of the global end of the trial : 18-Jun-2007), according to European Clinical Trials Database record.
- 26 Jul 2020 This trial has been completed in United Kingdom as per European Clinical Trials Database record ( global end of the trial 2007-06-18 )
- 01 Oct 2006 New trial record.